Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRYNOVIN vs BUPRENEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Treatment of opioid dependence,Management of moderate to severe pain (off-label)
Adult: 150 mg orally twice daily.
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (Cr Cl < 30 m L/min).
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism by CYP3A4.
Primarily N-dealkylation via CYP3A4; also conjugation by UGT enzymes (UGT1A1, UGT2B7).
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
96% bound to alpha- and beta-globulins, and albumin.
1.5 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments.
Volume of distribution is 430-600 L (approximately 2.8 L/kg), indicating extensive tissue distribution.
Oral: 75% (range: 60-90%) with minimal first-pass metabolism; intravenous: 100%.
Sublingual: 30-50% (due to first-pass metabolism); buccal: 50-60%; oral: 15-30% (not clinically used); intravenous: 100%.
Cr Cl 30-59 m L/min: 75 mg twice daily; Cr Cl 15-29 m L/min: 50 mg twice daily; Cr Cl <15 m L/min or dialysis: 25 mg once daily.
No specific dose adjustment required for GFR >30 m L/min; for GFR 15-30 m L/min, consider cautious dosing and extended intervals; for GFR <15 m L/min, use with caution and consider dose reduction.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: 50 mg twice daily.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use or reduce dose by 75%.
Children ≥12 years and ≥40 kg: 150 mg twice daily; <40 kg: 5 mg/kg/dose twice daily (max 150 mg/dose).
Not recommended for children under 2 years; for age 2-12 years: 2-6 mcg/kg intramuscularly or intravenously every 4-6 hours; maximum single dose 0.3 mg.
No specific dose adjustment, but monitor renal function; start at lower end of dosing range if renal impairment.
Start with 0.15 mg intramuscularly or intravenously every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
None.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of death with intravenous administration; risk of serious adverse events when used with benzodiazepines or other CNS depressants.
Ketoacidosis: Monitor for signs of ketoacidosis, including euglycemic ketoacidosis,Lower limb amputation: Consider risk factors prior to initiation; monitor for signs of infection or ulceration
Respiratory depression; CNS depression; risk of dependence and abuse; adrenal insufficiency; QT prolongation; severe injection site reactions; risk of precipitating withdrawal in opioid-dependent patients; neonatal withdrawal syndrome; impairment of ability to drive or operate machinery.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease on dialysis,History of serious hypersensitivity reaction to brynoxin or any excipient in the formulation
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe asthma; GI obstruction; elevated CSF pressure; use of MAOIs within 14 days.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Avoid alcohol as it may increase hepatotoxicity risk. Take with food to reduce gastrointestinal upset.
No specific food interactions are reported. Grapefruit juice has not been shown to significantly alter buprenorphine metabolism. Advise patients to maintain a balanced diet to manage opioid-induced constipation.
First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation signal; monitor fetal growth. Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties) at delivery if used near term.
Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) and neonatal respiratory depression. Risk of preterm labor and low birth weight. Use only if benefit outweighs risk.
Excreted in breast milk in low amounts (M/P ratio 0.2–0.4). Considered compatible with breastfeeding; monitor infant for sedation or gastrointestinal effects.
Buprenorphine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.9. Limited data suggest no adverse effects in breastfed infants at maternal doses up to 24 mg/day. However, monitor infant for sedation and respiratory depression. Benefits of breastfeeding outweigh risks in opioid-dependent mothers on maintenance therapy.
Due to increased volume of distribution and enhanced hepatic clearance in second and third trimesters, the dose may need to be increased by 20–40% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring (trough levels) recommended every 2 weeks with target range 5–15 mcg/m L. Postpartum: reduce dose to pre-pregnancy level within first week.
No specific dose adjustments are recommended for buprenorphine during pregnancy. However, due to increased plasma volume and hepatic clearance, some patients may require dose increases in the second and third trimesters to avoid withdrawal symptoms. Close monitoring of therapeutic response and withdrawal signs is advised.
Monitor renal function and electrolytes before and during therapy. Use with caution in patients with pre-existing cardiac disease due to risk of QT prolongation. Adjust dose in hepatic impairment (Child-Pugh B or C). Contraindicated with strong CYP3A4 inducers.
Buprenorphine (Buprenex) is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu-receptors, which can precipitate withdrawal if given to opioid-dependent patients. Monitor for respiratory depression, especially in combination with CNS depressants. Use with caution in hepatic impairment; adjust dose in moderate to severe impairment.
Take exactly as prescribed; do not skip doses or double up.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection, unusual bruising, or yellowing of skin or eyes.,Use effective contraception during treatment and for 3 months after last dose.,Do not drive if you experience dizziness or blurred vision.
Do not stop taking this medication abruptly as it may cause withdrawal symptoms; follow your doctor's instructions for tapering.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness or respiratory depression.,This medication can cause constipation; increase fluid and fiber intake, and consider stool softeners.,Store securely away from children and pets, as accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRYNOVIN vs BUPRENEX, answered by our medical review team.
BRYNOVIN is a Opioid Partial Agonist that works by Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.. BUPRENEX is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRYNOVIN and BUPRENEX depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRYNOVIN is: Adult: 150 mg orally twice daily.. The standard adult dose of BUPRENEX is: 0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRYNOVIN and BUPRENEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRYNOVIN is classified as Category C. First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation . BUPRENEX is classified as Category C. Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.